Nona Biosciences partners with Vienna medical school to advance fully human antibodies for infectious diseases
Executive summary: Nona Biosciences entered a research collaboration with the Medical University of Vienna to advance fully human antibody development for infectious diseases using its H2L2 Harbour Mice platform. The partnership could accelerate novel antibody therapeutics for infections, addressing unmet medical needs and strengthening Nona’s biologics pipeline.
Who is involved: Nona Biosciences, Medical University of Vienna (Ignaz Semmelweis Institute), and the H2L2 Harbour Mice technology platform.
Likely next: Preclinical studies will begin, with IND‑enabling data potentially available within the next 12‑18 months.
Nona Biosciences has teamed up with the Medical University of Vienna’s Ignaz Semmelweis Institute to employ its H2L2 Harbour Mice transgenic platform in the search for fully human antibodies targeting infectious diseases. The collaboration grants academic researchers access to Nona’s proprietary mouse model, aiming to translate early-stage discoveries into therapeutic candidates. This move reflects a broader trend of biotech firms leveraging specialized animal models to accelerate antibody drug discovery.
Timeline
- — Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases (PR Newswire)
- — Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting (PR Newswire)
Analysis — what this means
Sectors affected
- antibody therapeutics
- infectious disease research
- obesity drug development
Sources
- Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases — PR Newswire
- Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting — PR Newswire